Welcome to our Blog
(800) 267-5486

Monday, June 10, 2019

Together in Teal - Ending Ovarian Cancer at the Illinois Chapter 22nd Annual Run Walk

The National Ovarian Cancer Coalition (NOCC) Illinois Chapter 22nd Annual Run Walk, Together in TEAL® - Ending Ovarian Cancer, took place on Saturday, May 18, 2019 at the United Center.

The chapter is comprised of ovarian cancer survivors, supporters, and health care professionals committed to raising awareness, promoting education, and raising funds for ovarian cancer research.

Each member is dedicated to improving survival rates, as well as improving the quality of life for women affected by ovarian cancer.

AmpliVox has joined the effort to save lives and support the fight against ovarian cancer by donating a custom made Pinnacle Multimedia Lectern that was used for the event.

The custom Pinnacle Multimedia Lectern was created in the NOCC representative teal color, personalized with the organization's logo on the front panel for a truly unique and memorable presence on stage.

Virtually indestructible, Pinnacle lecterns are constructed of hard shell plastic that make them weatherproof, waterproof, rugged and durable for outdoor or indoor use.

Its presence will help to connect with new audiences and heighten the awareness and education on the importance of the early detection of ovarian cancer.

"We’ve affirmed our ongoing commitment to the fight against ovarian cancer, which AmpliVox supports", says Don Roth, CEO of AmpliVox.

"Donating the Teal Podium to the NOCC for presentations and events is our way of allowing all voices to be heard."

The NOCC is the premier public health organization in the United States devoted to saving and improving the lives of women affected by ovarian cancer.

For more than 25 years, the NOCC has been committed to raising awareness, promoting education, and funding research in support of women, families, and communities impacted by ovarian cancer.

In the past two years alone, the NOCC has made a tremendous impact in the fight against ovarian cancer.